Kinnari Patel
Presidente en ROCKET PHARMACEUTICALS, INC. .
Fortuna: 11 M $ al 31/05/2024
Cargos activos de Kinnari Patel
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Director de Operaciones | 04/01/2018 | - |
| Director Técnico/Científico/I+D | 27/03/2024 | - | |
| Presidente | - | - |
Historial de carrera de Kinnari Patel
Antiguos cargos conocidos de Kinnari Patel.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Rocket Pharmaceuticals Ltd.
 Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Director de Operaciones | 01/01/2018 | 01/02/2021 |
| Consejero General | 01/04/2016 | 01/12/2017 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/11/2010 | 01/04/2014 |
Formación de Kinnari Patel.
| The Leonard N Stern School of Business | Masters Business Admin |
| University of the Sciences in Philadelphia | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 6 |
Operativa
| Chief Operating Officer | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| President | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Empresas privadas | 1 |
|---|---|
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Kinnari Patel
- Experiencia
